Sprint Bioscience: Day One discontinues the VRK1 program - Redeye

During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue the license and the collaboration with Sprint Bioscience based on the VRK1 program. This is a major disappointment, and we expect Sprint Bioscience to review both the strategy and the operational cost base in the future.

Länk till analysen i sin helhet: https://www.redeye.se/research/1107151/sprint-bioscience-day-one-discontinues-the-vrk1-program?utm_source=finwire&utm_medium=RSS